OX40 levels distinguished DIHS/DRESS from other inflammatory dermatologic conditions, and were associated with HHV-6 reactivation
Systematic review and meta-analysis confirm an association, but not a causal link, between HHV-6 and CFS
HHV-6 was the most prevalent virus in febrile neutropenia episodes among pediatric patients
Significant positive correlations were found between HERV family proteins and antibodies to HHV-6A/B but not antibodies to EBV
U20/21 genes may help HHV-6A evade immune response
Studies conducted on serum obtained before development of MS indicate possible protective role
A viral miRNA disrupts mitochondrial architecture, suppresses type I interferon production, is necessary for productive infection and for virus reactivation, all by inhibiting multiple members of the host miR-30 family—creating a therapeutic target to suppress reactivation.
HHV-6 seronegativity pre-transplantation predicts HHV-6 viremia post-transplantation
Chromatin interactions help silence transcription of HHV-6A genes following integration
HHV-6B infection of primary monocytes induces cell-associated and soluble PD-L1 production, increased intracellular ROS and activation of STAT1 and STAT3 pathways
High-grade HHV-6 viremia is independently associated with rejection of liver transplants within 12 months
Patients with low levels of HHV-6 antibodies might benefit from treatment from IVIG or novel neutralizing antibodies before cord blood transplantation
The combination of gQ1 and gQ2 tetramer components of both HHV-6A/6B are important for viral propagation, probably by affecting attachment to their different receptors.
EBV, CMV, and HHV-6 reactivation were found in a small cohort of severe COVID-19 patients
Use of serum more easily distinguishes viremia from latent virus